Research Reports

The Sydney MSIC commenced operation in May 2001 for a trial period of 18-months. The initial evaluation covered the period May 2001 to October 2002. Following consideration of the results of the evaluation, the trial was extended to October 2007 and the NSW Health Department commissioned the National Centre in HIV Epidemiology and Clinical Research (NCHECR) to undertake a second evaluation covering the period November 2002 to April 2007. The current evaluation is directed by a comprehensive evaluation protocol and overseen by an Advisory Committee.

The Sydney Medically Supervised Injecting Centre (MSIC) evolved out of the NSW Parliamentary Drug Summit in 1999, which supported an 18-month trial of a medically supervised injecting centre, recognising that its operation may have both public health and public order benefits.

The Sydney Medically Supervised Injecting Centre (MSIC) evolved out of the NSW Parliamentary Drug Summit in 1999, which supported an 18-month trial of a single medically supervised injecting centre in Kings Cross, recognising that its operation may have both public health and public order benefits.

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

Little is known about the HIV-related knowledge, sexual behaviour and testing patterns of culturally and linguistically diverse (CALD) populations in Australia. This 2012 survey aimed to describe the knowledge, risk behaviour, and health service usage among people of Thai, Khmer, Zimbabwean, Ethiopian, Sudanese and South African backgrounds in NSW; and to establish an evidence-base to support policy and program interventions with these groups.